|
| Status |
Public on Oct 23, 2019 |
| Title |
c114416_rnaseq_uziel_22rv1_18: 22RV1_DHT ENZ rep2 |
| Sample type |
SRA |
| |
|
| Source name |
22RV1 immortalized prostate cancer cell line
|
| Organism |
Homo sapiens |
| Characteristics |
cell line: 22RV1
tissue: prostate adenocarcinoma cancer cell line
|
| Treatment protocol |
Cells were pretreated with indicated inhibitors for 45 minutes followed by 24 hr stimulation with 5 nM DHT or EtOH.
|
| Growth protocol |
22RV1 cells were grown for 72 hrs in charcoal stripped (steroid free) serum.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was prepared by Qiazol extraction followed by RNeasy mini column (QIAGEN)
10 ug of total RNA was submitted to poly-A selection to remove ribosomal RNA and reverse transcribed to double-stranded cDNA. The cDNA was eblunt ended, adenylated, and ligated with Illumina indexes.
|
| |
|
| Library strategy |
RNA-Seq |
| Library source |
transcriptomic |
| Library selection |
cDNA |
| Instrument model |
Illumina HiSeq 3000 |
| |
|
| Data processing |
Illumina Casava1.8 software used for basecalling
Reads were aligned using the OmicSoft aligner and gene expression quantified based on UCSC gene model.
Differentially expressed genes between treatment conditions detected by DESeq2 with a statistical cut-off (FC>2, p<0.01)
Genome_build: B37
Supplementary_files_format_and_content: FPKM value of all samples
|
| |
|
| Submission date |
Apr 24, 2019 |
| Last update date |
Oct 23, 2019 |
| Contact name |
Xin Lu |
| E-mail(s) |
xin.x.lu@abbvie.com
|
| Phone |
847-937-7942
|
| Organization name |
Abbvie
|
| Department |
Oncology Discovery
|
| Street address |
1 North Waukegan Rd
|
| City |
North Chicago |
| State/province |
IL |
| ZIP/Postal code |
60064 |
| Country |
USA |
| |
|
| Platform ID |
GPL21290 |
| Series (2) |
| GSE130247 |
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability (22RV1 RNA-seq) |
| GSE130269 |
Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability |
|
| Relations |
| BioSample |
SAMN11490539 |
| SRA |
SRX5729312 |
